Europe – Pilot project ‘Market Launch of Centrally Authorised Products’

The Pharmaceutical Strategy for Europe highlights the importance of patients’ access to
medicines. Innovative and promising therapies do not always reach the patient, so patients in the EU still have different levels of access to medicines.
Companies are not obliged to market a medicine in all EU countries; they may decide not to market their medicines in one or more countries. This can be due to various factors, such as national pricing and reimbursement policies, size of the population, the organisation of health systems and national administrative procedures resulting in smaller and less wealthy markets in particular facing these problems. Furthermore, due to operational limitations, smaller pharmaceutical companies may be unable to launch a newly authorised medicinal product in all Member States…